01 / DESIGN
What was studied?
A randomized placebo-controlled phase 3 study examined retatrutide in adults with both obesity and type 2 diabetes.
02 / FINDINGS
What did the researchers report?
Retatrutide produced greater weight reductions than placebo and improved glycemic measures. The study also reported adverse events within the defined trial population.
03 / LIMITS
How should it be interpreted?
Interpret the reported effect estimates and tolerability within this trial's estimands and eligibility criteria. Results concern a defined investigational formulation, not interchangeable research products.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.